Introduction to RNA Vaccines Post COVID-19.

Area of Science:

• Vaccinology and Immunology
• Molecular Biology
• Biotechnology

Background:

• Prophylactic vaccines currently prevent numerous infectious diseases.
• Future vaccinology aims to address emerging pathogens, intractable infections, and non-infectious diseases.
• RNA vaccines utilize genetic information for antigen expression, offering advantages over traditional protein antigens.

Purpose of the Study:

• To review key developments in RNA vaccine technology.
• To highlight the potential of RNA vaccines for future applications in vaccinology and immunotherapy.
• To provide an overview of the contents of the Methods in Molecular Biology volume on RNA vaccines.

Main Methods:

• Messenger RNA-lipid nanoparticle (mRNA-LNP) vaccine technology.
• Utilizing short-lived genetic information for protein antigen expression.
• Review of existing research and advancements in RNA vaccine development.

Main Results:

• mRNA-LNP vaccines have demonstrated clinical value, notably during the COVID-19 pandemic.
• These vaccines combine benefits of subunit and live-attenuated vaccines, including flexible production and immune stimulation.
• RNA vaccines stimulate both humoral and cellular immunity and possess self-adjuvanting properties.

Conclusions:

• RNA vaccines represent a significant advancement in vaccinology.
• Their mechanistic versatility positions them as a key tool for future immunotherapy and disease prevention.
• Ongoing development holds promise for broader applications beyond infectious diseases.